-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CUSP-06 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CUSP-06 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CUSP-06 in Ovarian Cancer Drug Details: CUSP-06 (AMT-707) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CUSP-06 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CUSP-06 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CUSP-06 in Solid Tumor Drug Details: CUSP-06 (AMT-707) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ifezuntirgene Inilparvovec in Huntington Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ifezuntirgene Inilparvovec in Huntington Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ifezuntirgene Inilparvovec in Huntington Disease Drug Details: Ifezuntirgene inilparvovec (AMT-130)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-151 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AMT-151 in Solid Tumor Drug Details: AMT-151 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Autogene Cevumeran in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Autogene Cevumeran in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Autogene Cevumeran in Pancreatic Ductal Adenocarcinoma Drug Details: Autogene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lanacogene Vosiparvovec in Hemophilia B (Factor IX Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lanacogene Vosiparvovec in Hemophilia B (Factor IX Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lanacogene Vosiparvovec in Hemophilia B (Factor IX Deficiency)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-260 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-260 in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-260 in Epilepsy Drug Details: AMT-260 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Luspatercept in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luspatercept in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luspatercept in Myelofibrosis Drug Details: Luspatercept-AMT (Reblozyl) is a recombinant fusion protein, it...
-
Product Insights
NewNet Present Value Model: UniQure NV’s AMT-130
Empower your strategies with our Net Present Value Model: UniQure NV's AMT-130 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Sector Analysis
Automotive Transmission and Clutch Technologies Market Trends, Sector Overview and Forecast to 2028
Automotive Transmission and Clutch Technologies Market Overview The transmission and clutch technologies market size was 175.8 million units in 2023. The market will grow at a CAGR of more than 2% during 2023-2028. The market growth is primarily attributed to the stringent fuel efficiency and emission regulations worldwide that are prompting manufacturers to focus on fuel-efficient transmission systems. In 2023, Asia-Pacific accounted for a significant share of the automotive transmission and clutch technologies market. Automotive Transmission and Clutch Technologies Market...